Symbiotec Pharmalab's Q1 FY 2026-27 Quarterly Results

Result Summary

• Symbiotec Pharmalab Ltd reported a - quarter-on-quarter (QoQ) - in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a - of -.
• Its expenses for the quarter were - by - QoQ and - - YoY.
• The net profit - - QoQ and - - YoY.
• The earnings per share (EPS) of Symbiotec Pharmalab Ltd stood at 2.24 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Symbiotec Pharmalab Ltd is a company primarily engaged in the pharmaceutical industry. The company is known for its production and supply of active pharmaceutical ingredients (APIs) and intermediates, which are essential components in drug manufacturing. Symbiotec has established a significant presence in the healthcare sector, focusing on developing products that cater to various therapeutic categories. While specific recent developments for Symbiotec Pharmalab Ltd are not provided in the available data, the company operates in a highly competitive and regulated industry where innovation and compliance with health standards are critical for success.

Revenue

In Q1FY27, Symbiotec Pharmalab Ltd reported a total income of ₹218.49 crores. This figure represents the entirety of the company's revenue streams for the quarter. Due to the absence of comparable financial data for Q4FY26 and Q1FY26, it is not possible to calculate the quarter-over-quarter (QoQ) and year-over-year (YoY) changes in total income. However, the reported total income serves as a key indicator of the company's revenue performance for the quarter, reflecting its ability to generate sales and other income through its business operations.

Profitability

For Q1FY27, Symbiotec Pharmalab Ltd achieved a profit before tax of ₹17.53 crores. After accounting for a tax expense of ₹3.47 crores, the company recorded a profit after tax of ₹14.06 crores. This establishes the company's net earnings for the quarter, providing insight into its profitability. The earnings per share (EPS) for the quarter stood at ₹2.24, reflecting the company's ability to generate profit attributable to each share of its equity. Due to the lack of prior period data, QoQ and YoY profitability changes could not be determined. These metrics are important for evaluating the company’s financial health and efficiency in managing expenses relative to its income.

Operating Metrics

The financial data for Q1FY27 indicates total expenses of ₹200.95 crores for Symbiotec Pharmalab Ltd. This figure represents the costs incurred in the production and delivery of the company's products and services. While the data does not provide detailed breakdowns of operating expenses, such as cost of goods sold or operating expenses, the total expenses amount is crucial for assessing the company’s operational efficiency. The ratio of total expenses to total income can be used to infer the company's cost management effectiveness, but specific ratios such as the current ratio or debt-to-equity ratio cannot be calculated due to the absence of additional financial information.